{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:32:33Z","timestamp":1764783153136},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T00:00:00Z","timestamp":1262044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>An international, non\u2010randomised study evaluated efficacy and safety of risperidone long\u2010acting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with schizophrenia or other psychotic disorder, symptomatically stable on antipsychotic medication, received intramuscular injections of RLAI 25\u2009mg (to a maximum of 50\u2009mg) every 2 weeks for 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 182 UK patients enrolled, 79% had schizophrenia, 21% other psychotic disorders. Insufficient efficacy (43%), side effects (45%), and non\u2010compliance (25%) were the most common reasons for switching. Sixty\u2010nine per cent of patients completed the trial; 8% discontinued due to adverse events (AEs). Most frequent treatment\u2010emergent AEs were headache (8.2%), relapse (7.7%) and insomnia (7.1%); 8 (4.4%) patients reported injection\u2010related AEs. There were significant improvements in extrapyramidal symptom rating scale total and subscale (particularly Parkinsonism) scores, regardless of previous medication (total cohort, <jats:italic>p<\/jats:italic>\u22640.0001). There was a small but significant increase in body weight at endpoint (1.2kg, <jats:italic>p<\/jats:italic>\u2009=\u20090.0023). One patient suffered a myocardial infarction and died (not treatment\u2010related). There were no substantial differences between the full data set and the UK sub\u2010population<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Switch to RLAI was well\u2010tolerated in stable patients over 6 months. The European data set is generalisable to the UK patient population. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1085","type":"journal-article","created":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T14:53:52Z","timestamp":1262098432000},"page":"37-46","source":"Crossref","is-referenced-by-count":15,"title":["Switching stable patients with schizophrenia from depot and oral antipsychotics to long\u2010acting injectable risperidone: reasons for switching and safety"],"prefix":"10.1002","volume":"25","author":[{"given":"Chris","family":"Hawley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammud A","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivienne","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Packeruther T","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,29]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.4.290"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta7130"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1104"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199511000-00001"},{"issue":"7","key":"e_1_2_1_7_1","first-page":"4","article-title":"Antipsychotic\u2010induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65","author":"Casey DE","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_8_1","first-page":"233","article-title":"The extrapyramidal symptom rating scale","volume":"7","author":"Chouinard G","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.07.003"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.11.001"},{"issue":"16","key":"e_1_2_1_12_1","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky L","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1017"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7273.1371"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7002.421"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0110"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1105"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31814f3178"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0107"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0809"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.08.004"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200507000-00004"},{"key":"e_1_2_1_27_1","article-title":"Switching stable patients with schizophrenia from depot and oral antipsychotics to long\u2010acting injectable risperidone: efficacy, quality of life and functional outcome","author":"Lloyd KR","journal-title":"Hum Psychopharmacol."},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17215"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200505000-00001"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767110-00003"},{"key":"e_1_2_1_31_1","volume-title":"Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care","author":"National Institute for [Health and] Clinical Excellence","year":"2003"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651060-00001"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/apt.11.3.203"},{"issue":"64","key":"e_1_2_1_34_1","first-page":"14","article-title":"Relapse and rehospitalization: comparing oral and depot antipsychotics","volume":"64","author":"Schooler NR","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199706000-00010"},{"key":"e_1_2_1_36_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup TS","year":"2007","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2008.59.5.500"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000133500.92025.20"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007076"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00154-1"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1085","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:30:20Z","timestamp":1700555420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/hup.1085"],"URL":"https:\/\/doi.org\/10.1002\/hup.1085","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,29]]}}}